Drug Trial Radar · NCT01492361
A Study of AMR101 to Evaluate Its Ability to Reduce Cardiovascular Events in High-Risk Patients With Hypertriglyceridemia and on Statin
Last checked: Nov 19, 2026Latest source record: Apr 14, 2022 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
8,179
Actual
Start
Nov 2011
Primary completion
May 2018
Study completion May 2018
Sponsor
- Lead sponsor
- Amarin Pharma Inc.Industry
- Sponsor type
- Industry
- First posted
- Dec 15, 2011
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Triple (participant, investigator, outcomes assessor)
- Primary purpose
- Prevention
- Who can join
- All sexes, from 45 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
AMR101 (icosapent ethyl \[ethyl-EPA\]) is a highly purified ethyl ester of eicosapentaenoic acid (EPA) developed by Amarin Pharma Inc. for the treatment of cardiovascular disease in statin-treated patients with hypertriglyceridemia. The purpose of this study was to evaluate whether this drug, combined with a statin therapy, will be superior to the statin therapy alone, when used as a prevention in reducing long-term cardiovascular events in high-risk patients with mixed dyslipidemia.
Conditions
- Cardiovascular Diseases
Interventions
AMR101Drug
Parallel Assignment
PlaceboDrug
Parallel Assignment
Statin therapyDrug
Stable statin therapy (± ezetimibe) for at least 28 days before lipid qualification measurement (LDL-C \>40 mg/dL and ≤100 mg/dL)
Primary outcomes
What the sponsor says the trial is designed to measure.
- Composite of CV Death, Nonfatal MI (Including Silent MI), Nonfatal Stroke, Coronary Revascularization, or Unstable Angina Determined to be Caused by Myocardial Ischemia by Invasive / Non-invasive Testing and Requiring Emergent Hospitalization.Time frame: Total follow-up time of up to approximately 6 years.
Locations
410 sites in 11 countries. Site status is shown where the registry gives one.
Amarin Investigational Site
Birmingham, Alabama
Amarin Investigational Site
Birmingham, Alabama
Amarin Investigational Site
Huntsville, Alabama
Amarin Investigational Site
Mobile, Alabama
Amarin Investigational Site
Muscle Shoals, Alabama
Amarin Investigational Site
Mesa, Arizona
Amarin Investigational Site
Phoenix, Arizona
Amarin Investigational Site
Tucson, Arizona
Amarin Investigational Site
Little Rock, Arkansas
Amarin Investigational Site
Beverly Hills, California
Amarin Investigational Site
Chino, California
Amarin Investigational Site
Concord, California
Amarin Investigational Site
El Cajon, California
Amarin Investigational Site
Encino, California
Amarin Investigational Site
Fair Oaks, California
Amarin Investigational Site
Hawaiian Gardens, California
Amarin Investigational Site
Lancaster, California
Amarin Investigational Site
Lincoln, California
Amarin Investigational Site
Los Angeles, California
Amarin Investigational Site
Los Angeles, California
Amarin Investigational Site
Los Angeles, California
Amarin Investigational Site
National City, California
Amarin Investigational Site
Orange, California
Amarin Investigational Site
Paramount, California
Amarin Investigational Site
Roseville, California
Amarin Investigational Site
San Diego, California
Amarin Investigational Site
Torrance, California
Amarin Investigational Site
Ventura, California
Amarin Investigational Site
Walnut Creek, California
Amarin Investigational Site
Aurora, Colorado
Amarin Investigational Site
Colorado Springs, Colorado
Amarin Investigational Site
Golden, Colorado
Amarin Investigational Site
Guilford, Connecticut
Amarin Investigational Site
Hartford, Connecticut
Amarin Investigational Site
Newark, Delaware
Amarin Investigational Site
Wilmington, Delaware
Amarin Investigational Site
Washington D.C., District of Columbia
Amarin Investigational Site
Boynton Beach, Florida
Amarin Investigational Site
Bradenton, Florida
Amarin Investigational Site
Clearwater, Florida
Showing 40 of 410 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.